Alpha Tau to Participate in December Investor Conferences
Rhea-AI Summary
Alpha Tau (NASDAQ: DRTS, DRTSW) announced that CFO Raphi Levy will present at two investor conferences in December 2025: a Fireside Chat at the 37th Annual Piper Sandler Healthcare Conference on Dec 3, 2025, 1:00–1:25 PM ET in New York, and a Company Presentation at Sidoti's Year End Virtual Investor Conference on Dec 10, 2025, 11:30 AM–12:00 PM ET.
Mr. Levy will be available for 1x1 investor meetings at both events; investors should contact their Piper Sandler or Sidoti representatives to schedule.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Down
DRTS rose 19.62%, while biotech peers were mixed: ADCT up 4.5%, AUTL up 3.25%, IMRX up 1.81%, but ALDX down 4.57% and TECX down 3.04%, suggesting a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | GBM trial progress | Positive | +8.7% | First GBM patient treated in U.S. pilot study with Alpha DaRT. |
| Dec 04 | Pancreatic cancer data | Positive | +4.6% | Two Alpha DaRT pancreatic cancer abstracts accepted for 2026 ASCO GI. |
| Dec 02 | FDA IDE approval | Positive | +2.4% | FDA IDE approval to start pilot study in locally recurrent prostate cancer. |
| Dec 01 | Investor conferences | Neutral | -4.8% | Announcement of December investor conference presentations and 1x1 meetings. |
| Nov 20 | Q3 2025 earnings | Neutral | -5.7% | Q3 update with higher R&D, increased net loss, and strengthened cash resources. |
Recent clinically focused announcements (GBM, pancreatic, prostate programs) generally saw positive price reactions, while non-clinical items like conferences and earnings drew negative responses, indicating stronger alignment with clinical catalysts.
Over the last few weeks, DRTS has reported several milestones. On Nov 20, 2025, it posted Q3 results highlighting cash of $75.9M and increased R&D, which coincided with a -5.71% move. Later, FDA approval of a prostate cancer IDE on Dec 2 and pancreatic and GBM trial updates on Dec 4 and Dec 9 produced gains of 2.38%, 4.64%, and 8.74%. A prior investor-conference announcement on Dec 1 saw a -4.79% reaction, contrasting with today’s strong advance.
Market Pulse Summary
This announcement highlights Alpha Tau’s plan for investor outreach, with its CFO presenting at two December conferences and offering 1x1 meetings. In context, the company recently reported Q3 cash of $75.9M, a nine-month net loss of $30.5M, and increased R&D of $22.5M, alongside multiple U.S. trials in GBM, pancreatic, and prostate cancer. Investors may watch upcoming clinical updates, cash usage trends, and manufacturing scale-up toward the facility’s 400,000-source capacity.
Key Terms
alpha-radiation medical
AI-generated analysis. Not financial advice.
JERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present in the following investor conferences in December 2025.
| Event: | 37th Annual Piper Sandler Healthcare Conference |
| Format: | Fireside Chat |
| Date: | December 3, 2025 |
| Time: | 1:00 – 1:25PM ET |
| Location: | New York, NY |
| Event: | Sidoti's Year End Virtual Investor Conference |
| Format: | Company Presentation |
| Date: | December 10, 2025 |
| Time: | 11:30AM – 12:00PM ET |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your Piper Sandler and Sidoti representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
FAQ
When will Alpha Tau (DRTS) present at the Piper Sandler Healthcare Conference?
What are the date and time for Alpha Tau (DRTS) at Sidoti's Year End Virtual Investor Conference?
How can investors schedule 1x1 meetings with Alpha Tau CFO Raphi Levy at the December 2025 conferences?
What presentation formats will Alpha Tau use at the December 2025 events?
Will the Sidoti presentation by Alpha Tau (DRTS) be available remotely?
